Beyond drug discovery: How LogicFlo AI is fixing life sciences’ workflow crisis
LogicFlo AI, a Boston-based AI startup, employs agents to handle complex tasks, allowing human experts to maintain control over the final output.
The life sciences industry thrives on innovation, yet some of its brightest minds—PhDs, MDs, and researchers—are often consumed by paperwork. Instead of focusing on breakthroughs in drug development or patient care, these experts spend countless hours formatting regulatory submissions, reviewing scientific literature, and managing compliance workflows.
A 2023 KPMG report by Pharma Regulatory Compliance estimated that pharmaceutical companies spend up to 20% of operational time on compliance tasks like documentation, traceability, and audits, while a 2025 Pharmaphorum analysis notes that documentation alone can take up to 30% of staff time due to manual processes and limited automation. This inefficiency is estimated to cost the industry billions of dollars each year, slowing both scientific progress and the path to new therapies.
“It’s remarkable that an industry at the forefront of medical breakthroughs is still held back by outdated processes,” Udith Vaidyanathan, Co-founder and CEO of LogicFlo AI, tells YourStory. The ex-BCG employee specialises in pharma and life sciences; he served at the CEO’s office of a major pharmaceutical company during the COVID-19 pandemic.“I’ve seen doctors and medical writers spend weeks just piecing together references or formatting documents.”
In 2024, he teamed up with his childhood friend from Chennai, Arun Ramakrishnan, and founded LogicFlo AI with an undisclosed amount. “I’ve seen both sides, the value of rigorous SOPs and compliance, but also the inefficiencies they create,” says Vaidyanathan.
The Boston-headquartered startup tackles systemic inefficiencies in life sciences organisations—pharmaceutical, biotech, and medtech companies—by automating and streamlining high-compliance, knowledge-heavy workflows. These include medical writing, regulatory submissions, quality documentation, and commercial operations.
It deploys specialised AI agents trained on company-specific Standard Operating Procedures (SOPs), templates, and compliance frameworks. These agents handle the time-consuming, process-heavy tasks, while human experts remain fully in control of the final output.
“Our AI isn’t a generic co-pilot. It’s a domain expert designed to understand the complexities of regulated environments, medical, regulatory, quality, and commercial functions. We’re not replacing scientists or doctors. We’re enabling them to focus on science, strategy, and innovation, while AI does the heavy lifting,” he explains.
The scale of the challenge
The inefficiencies that LogicFlo addresses are not isolated—they are structural. While drug discovery and R&D benefit from advanced technologies and heavy funding, commercialisation and compliance processes remain largely manual. An estimated $360 billion is spent annually in life sciences on repetitive tasks which could be automated or streamlined.
“We know that modern AI could change this, but only if built with deep context, strict guardrails, and a thorough understanding of compliance requirements,” says Ramakrishnan, Co-founder and CTO of LogicFlo AI.
This conviction led to LogicFlo’s first pilot in May 2024 with a Fortune 500 life sciences enterprise. The startup says it saw a significant impact, with the documentation process becoming 20X quicker, transforming months of work into days, while costs dropped by 70-80%.
It has since secured a multi-year contract with the same enterprise, scaling deployment across 300 teams and 10,000 users globally, including in the US, Europe, India, and Southeast Asia.
A human-centric AI approach
LogicFlo AI’s agents operate under a human-in-the-loop framework, ensuring that while the AI manages drafting, data processing, and literature reviews, experts remain the final decision-makers.
“We’re not building a black-box AI. Think of our system as an AI-powered co-worker. It can process thousands of scientific papers in hours, surface the most relevant insights, and draft content, but the human expert is always in control of the output,” clarifies Ramakrishnan, who has a background in AI and robotics, and developed object detection systems for robotic surgery for Intuitive Surgical, where he worked closely with regulatory teams on FDA documentation.
This approach has earned strong validation from clients, the company says. In early company-sponsored studies, eight out of 10 doctors rated LogicFlo’s outputs as equally accurate or even better than human-only processes.
Technology and integration
LogicFlo AI’s platform is built around an orchestration framework rather than proprietary foundational models, allowing it to integrate seamlessly with fragmented tech stacks often found in life sciences organisations.
Its in-house domain-specific knowledge graph maps relationships between regulatory requirements, scientific data, and organisational content. Every AI-generated output is fully traceable back to its source, whether a research paper, PDF, or Excel file.
“Our platform is explainable by design,” Vaidyanathan emphasises. “Every line of content we generate can be traced back to its source, which is essential for regulatory submissions and medical communications.”
The system integrates with enterprise tools such as Veeva and IQVIA through modular architecture, APIs, and standardised protocols, enabling end-to-end workflows for regulatory authoring, quality checks, and commercial documentation.
The startup competes with players such as Bluenote Health, Atrix AI, Argon AI, and Collate. While talking about what makes it stand out in the market Vaidyanathan says, “Most AI tools in this space focus on generating content quickly, but they don’t address the complexity of regulated life sciences workflows.”
“Our focus is on building AI agents that work within strict compliance frameworks, integrate with existing enterprise tools, and provide outputs that are fully traceable and auditable. It’s less about speed alone and more about doing the work correctly in a regulated environment,” he adds.
Future plans
The global life science market is projected to experience a CAGR of 10.28% from 2025 to 2034, according to Cervicorn Consulting.
This year, LogicFlo secured $2.7 million in seed funding led by Lightspeed. Fortune 500 pharmaceutical clients and several global enterprises are piloting its platform, with deployments starting at 20-30 users per organisation and expanding to thousands across departments.
Currently, the startup operates with a lean team of four, with plans to grow to seven by the end of 2025. LogicFlo claims it is already driving measurable productivity gains in regulatory filings, literature reviews, medical information responses, and quality documentation.
LogicFlo AI is currently focused on the US market, where regulatory and compliance workflows present the highest demand for its solutions. However, the team plans to expand globally, tailoring the platform to region-specific regulations and localisation requirements.
(Disclaimer: The story has been updated to correct factual errors.)
Edited by Kanishk Singh